Fondaparinux or enoxaparin: A comparative study of postoperative bleeding in coronary artery bypass grafting surgery

Scandinavian Cardiovascular Journal

Volumn 44, Issue 2, 2010, Pages 100-106

  Landenhed, Maya ^a   Johansson, Malin ^a   Erlinge, David ^a   Olsson, Martin L ^b,c   Bjursten, Henrik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b University and Regional Laboratories   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bleeding; Coronary artery bypass grafting; Enoxaparin; Fondaparinux; Safety

Indexed keywords

ENOXAPARIN; FONDAPARINUX;

AGED; ARTICLE; BLOOD TRANSFUSION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949578901     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017430903388334     Document Type: Article

References (25)

1. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996;347:561-568
2. Long-term low-molecular-mass heparin in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet. 1999;354:701-707
3. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non- ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007; 50:e1-e157.
4. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660
5. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et al. Antithrombotic therapy for non- ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest. 2008;133:670S-707S.
6. Bassand JP, Hamm C. Guidelines for anticoagulant use in acute coronary syndromes. Lancet. 2008;372:532-3; author reply 3-4.
7. Bassand JP. The place of fondaparinux in the ESC and ACC/ AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. Eur Heart J Suppl. 2008:C22-C29.
8. Gulbins H, Malkoc A, Ennker IC, Ennker J. Preoperative platelet inhibition with ASA does not infl uence postoperative blood loss following coronary artery bypass grafting. Thorac Cardiovasc Surg. 2009;57:18-21.
9. Kincaid EH, Monroe ML, Saliba DL, Kon ND, Byerly WG, Reichert MG. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2003;76:124-8; Discussion 8.
10. Purkayastha S, Athanasiou T, Malinovski V, Tekkis P, Foale R, Casula R, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart. 2006;92:531-532
11. Kunadian B, Thornley AR, Tanos M, Dunning J. Should clopidogrel be stopped prior to urgent cardiac surgery? Interact Cardiovasc Thorac Surg. 2006;5:630-636
12. Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: A multicenter analysis. J Am Coll Cardiol. 2008;52:1693-1701
13. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476
14. Turpie AG. Selective factor Xa inhibition with forndaparinux: From concept to clinical benefi t. Eur Heart J Suppl 2008; 10:C1-C7.
15. JL A. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-executive summary. J Am Coll Cardiol. 2007;50: 652-726.
16. Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ, et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2005;27:592-598
17. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, et al. Effi cacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50: 1742-1751
18. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA. 2006;295:1519-1530
19. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood. 2005;105:139-144
20. Neykova A. The HIT treatment in a cardiac surgery patient. Int J Cardiol. 2009 (in press).
21. Everett BM, Yeh R, Foo SY, Criss D, Van Cott EM, Laposata M, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597
22. Alsaleh KA, Al-Nasser SM, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol. 2008;83:876-878
23. Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: Shortterm cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157:845-852
24. Kim JH, Newby LK, Clare RM, Shaw LK, Lodge AJ, Smith PK, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J. 2008;156:886-892
25. Shim JK, Choi YS, Oh YJ, Bang SO, Yoo KJ, Kwak YL. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2007;134:59-64.